Nagaraju Sarabu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nagaraju Sarabu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
J. Augustine
Department of Surgery, University Hospitals Case Medical Center, Cleveland, OH
5 shared publicationsD. Cote
Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, OH
3 shared publicationsE. Sanchez
Department of Surgery, University Hospitals Case Medical Center, Cleveland, OH
3 shared publicationsJ. Schulak
University Hospitals Case Medical Center, Cleveland, OH
3 shared publicationsK. Woodside
Department of Surgery, University Hospitals Case Medical Center, Cleveland, OH
3 shared publications- Krista L. Lentine
SSM Health Saint Louis University Hospital, United States
3 shared publications
Latest Publications
- Open Access
- 21 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (10) , e7027
Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end‐stage kidney disease
Background: Black men and men with end‐stage kidney disease have lower rates of treatment and higher mortality for prostate cancer. We studied the interaction of end‐stage kidney disease (ESKD) with Black race for treatment rates and mortality for men with prostate cancer.Methods and Results: We included 516 Black and 551 White men with ESKD before prostate cancer 22,299 Black men, and 141,821 White men without ESKD who were 40 years or older from the Surveillance, Epidemiology, and End‐Results‐Medicare data (2004–2016). All Black men with or without ESKD and White men with ESKD had higher prostate‐specific antigen levels at diagnosis than White men without ESKD. Black men with ESKD had the lowest rates for treatment in both local and advanced stages of prostate cancer (age‐adjusted risk ratio: 0.76, 95% Confidence Interval (CI): 0.71–0.82 for local stage and age‐adjusted risk ratio: 0.82, 95% CI: 0.76–0.9 for advanced stages) compared to White men without ESKD. Compared to White men without ESKD, prostate cancer‐specific mortality was higher in White men with ESKD for both local and advanced stages (age‐adjusted hazard ratio: 1.8, 95% CI: 1.2–2.8 and HR: 1.6, 95% CI: 1.2–2.2) and it was higher for ESKD Black men only in advanced stage prostate cancer (age‐adjusted hazard ratio: 2.4, 95% CI: 1.5–3.6).Conclusion: Our findings suggest that having a comorbidity such as ESKD makes Black men more vulnerable to racial disparities in prostate cancer treatment and mortality.
- 21 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (10) , e7027
Open AccessDisparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end‐stage kidney disease
Background: Black men and men with end‐stage kidney disease have lower rates of treatment and higher mortality for prostate cancer. We studied the interaction of end‐stage kidney disease (ESKD) with Black race for treatment rates and mortality for men with prostate cancer.Methods and Results: We included 516 Black and 551 White men with ESKD before prostate cancer 22,299 Black men, and 141,821 White men without ESKD who were 40 years or older from the Surveillance, Epidemiology, and End‐Results‐Medicare data (2004–2016). All Black men with or without ESKD and White men with ESKD had higher prostate‐specific antigen levels at diagnosis than White men without ESKD. Black men with ESKD had the lowest rates for treatment in both local and advanced stages of prostate cancer (age‐adjusted risk ratio: 0.76, 95% Confidence Interval (CI): 0.71–0.82 for local stage and age‐adjusted risk ratio: 0.82, 95% CI: 0.76–0.9 for advanced stages) compared to White men without ESKD. Compared to White men without ESKD, prostate cancer‐specific mortality was higher in White men with ESKD for both local and advanced stages (age‐adjusted hazard ratio: 1.8, 95% CI: 1.2–2.8 and HR: 1.6, 95% CI: 1.2–2.2) and it was higher for ESKD Black men only in advanced stage prostate cancer (age‐adjusted hazard ratio: 2.4, 95% CI: 1.5–3.6).Conclusion: Our findings suggest that having a comorbidity such as ESKD makes Black men more vulnerable to racial disparities in prostate cancer treatment and mortality.
- Open Access
- 16 January 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 7941-7950
Treatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study
Background: In accordance with guidelines, observation with or without active surveillance for low-risk prostate cancer increased in recent years in the general population. We compared treatment patterns and mortality for low- and intermediate-risk prostate cancer and mortality rates among end-stage kidney disease (ESKD) and non-ESKD patients.Methods: This is a retrospective population-based observational cohort study of Surveillance, Epidemiology, and End Results-Medicare data of men aged 66 years and older with localized prostate cancer (2004-2015). ESKD status was determined using Medicare billing codes. Multivariable logistic regression models and Cox-proportional hazards models were used to study definitive treatment patterns and mortality, respectively.Results: For low-risk prostate cancer, dialysis patients (N = 83) had lower but not statistically significant odds (OR, 0.74; 95% CI: 0.48-1.16) of receiving definitive treatment than non-ESKD patients (N = 24,935). For those with intermediate-risk prostate cancer, dialysis patients (N = 254) had lower odds to receive definitive treatment (OR, 0.54; 95% CI: 0.42-0.72) than non-ESKD patients (N = 60,883). From 2004-2010 to 2011-2015, for patients with low-risk prostate cancer, while the receipt of definitive treatment for non-ESKD patients trended down from 72% to 48%, it trended up for dialysis patients from 55% to 65%. Kidney transplant patients (N = 33 for low-risk and N = 91 for intermediate-risk) had lower rates of definitive treatment for low-risk and similar rates of treatment for intermediate-risk prostate cancer compared to non-ESKD patients.Conclusions: The disparity in definitive treatment rates for low-risk prostate cancer among dialysis patients exists despite their high mortality, compared to the general population.
- 16 January 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 7941-7950
Open AccessTreatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study
Background: In accordance with guidelines, observation with or without active surveillance for low-risk prostate cancer increased in recent years in the general population. We compared treatment patterns and mortality for low- and intermediate-risk prostate cancer and mortality rates among end-stage kidney disease (ESKD) and non-ESKD patients.Methods: This is a retrospective population-based observational cohort study of Surveillance, Epidemiology, and End Results-Medicare data of men aged 66 years and older with localized prostate cancer (2004-2015). ESKD status was determined using Medicare billing codes. Multivariable logistic regression models and Cox-proportional hazards models were used to study definitive treatment patterns and mortality, respectively.Results: For low-risk prostate cancer, dialysis patients (N = 83) had lower but not statistically significant odds (OR, 0.74; 95% CI: 0.48-1.16) of receiving definitive treatment than non-ESKD patients (N = 24,935). For those with intermediate-risk prostate cancer, dialysis patients (N = 254) had lower odds to receive definitive treatment (OR, 0.54; 95% CI: 0.42-0.72) than non-ESKD patients (N = 60,883). From 2004-2010 to 2011-2015, for patients with low-risk prostate cancer, while the receipt of definitive treatment for non-ESKD patients trended down from 72% to 48%, it trended up for dialysis patients from 55% to 65%. Kidney transplant patients (N = 33 for low-risk and N = 91 for intermediate-risk) had lower rates of definitive treatment for low-risk and similar rates of treatment for intermediate-risk prostate cancer compared to non-ESKD patients.Conclusions: The disparity in definitive treatment rates for low-risk prostate cancer among dialysis patients exists despite their high mortality, compared to the general population.
- Open Access
- 22 September 2022
- Published by Springer Nature in Current Transplantation Reports
- Vol. 9 (4) , 328-335
Managing the Costs of Routine Follow-up Care After Living Kidney Donation: a Review and Survey of Contemporary Experience, Practices, and Challenges
Purpose of Review: While living organ donor follow-up is mandated for 2 years in the USA, formal guidance on recovering associated costs of follow-up care is lacking. In this review, we discuss current billing practices of transplant programs for living kidney donor follow-up, and propose future directions for managing follow-up costs and supporting cost neutrality in donor care. Recent Findings: Living donors may incur costs and financial risks in the donation process, including travel, lost time from work, and dependent care. In addition, adherence to the Organ Procurement and Transplantation Network (OPTN) mandate for US transplant programs to submit 6-, 12-, and 24-month postdonation follow-up data to the national registry may incur out-of-pocket medical costs for donors. Notably, the Centers for Medicare and Medicaid Services (CMS) has explicitly disallowed transplant programs to bill routine, mandated follow-up costs to the organ acquisition cost center or to the recipient’s Medicare insurance. We conducted a survey of transplant staff in the USA (distributed October 22, 2020–March 15, 2021), which identified that the mechanisms for recovering or covering the costs of mandated routine postdonation follow-up at responding programs commonly include billing recipients’ private insurance (40%), while 41% bill recipients’ Medicare insurance. Many programs reported utilizing institutional allowancing (up to 50%), and some programs billed the organ acquisition cost center (25%). A small percentage (11%) reported billing donors or donors’ insurance. Summary: To maintain a high level of adherence to living donor follow-up without financially burdening donors, up-to-date resources are needed on handling routine donor follow-up costs in ways that are policy-compliant and effective for donors and programs. Development of a government-supported national living donor follow-up registry like the Living Donor Collective may provide solutions for aspects of postdonation follow-up, but requires transplant program commitment to register donors and donor candidates as well as donor engagement with follow-up outreach contacts after donation.
- 22 September 2022
- Published by Springer Nature in Current Transplantation Reports
- Vol. 9 (4) , 328-335
Open AccessManaging the Costs of Routine Follow-up Care After Living Kidney Donation: a Review and Survey of Contemporary Experience, Practices, and Challenges
Purpose of Review: While living organ donor follow-up is mandated for 2 years in the USA, formal guidance on recovering associated costs of follow-up care is lacking. In this review, we discuss current billing practices of transplant programs for living kidney donor follow-up, and propose future directions for managing follow-up costs and supporting cost neutrality in donor care. Recent Findings: Living donors may incur costs and financial risks in the donation process, including travel, lost time from work, and dependent care. In addition, adherence to the Organ Procurement and Transplantation Network (OPTN) mandate for US transplant programs to submit 6-, 12-, and 24-month postdonation follow-up data to the national registry may incur out-of-pocket medical costs for donors. Notably, the Centers for Medicare and Medicaid Services (CMS) has explicitly disallowed transplant programs to bill routine, mandated follow-up costs to the organ acquisition cost center or to the recipient’s Medicare insurance. We conducted a survey of transplant staff in the USA (distributed October 22, 2020–March 15, 2021), which identified that the mechanisms for recovering or covering the costs of mandated routine postdonation follow-up at responding programs commonly include billing recipients’ private insurance (40%), while 41% bill recipients’ Medicare insurance. Many programs reported utilizing institutional allowancing (up to 50%), and some programs billed the organ acquisition cost center (25%). A small percentage (11%) reported billing donors or donors’ insurance. Summary: To maintain a high level of adherence to living donor follow-up without financially burdening donors, up-to-date resources are needed on handling routine donor follow-up costs in ways that are policy-compliant and effective for donors and programs. Development of a government-supported national living donor follow-up registry like the Living Donor Collective may provide solutions for aspects of postdonation follow-up, but requires transplant program commitment to register donors and donor candidates as well as donor engagement with follow-up outreach contacts after donation.
- 20 April 2022
- Published by Elsevier in Kidney International
- Vol. 101 (5) , 1093-1094
The Case | A rare donor-derived cause of delayed graft function
- 20 April 2022
- Published by Elsevier in Kidney International
- Vol. 101 (5) , 1093-1094
The Case | A rare donor-derived cause of delayed graft function
- Open Access
- 29 September 2021
- Published by Elsevier in Kidney Medicine
- Vol. 3 (6) , 1032-1040
Prostate Cancer, Kidney Transplant Wait Time, and Mortality in Maintenance Dialysis Patients: A Cohort Study Using Linked United States Renal Data System Data
- 29 September 2021
- Published by Elsevier in Kidney Medicine
- Vol. 3 (6) , 1032-1040
Open AccessProstate Cancer, Kidney Transplant Wait Time, and Mortality in Maintenance Dialysis Patients: A Cohort Study Using Linked United States Renal Data System Data
- Open Access
- 2 March 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (5) , e018971
Outcomes of Surgical Mitral and Aortic Valve Replacements Among Kidney Transplant Candidates: Implications for Valve Selection
Background: Limited literature exists that evaluated outcomes of kidney transplant–eligible patients who are having dialysis and who are undergoing valve replacement. Our main objective in this study was to compare mortality, reoperation, and bleeding episodes between bioprosthetic and mechanical valve procedures among kidney transplant–eligible patients who are having dialysis. Methods and Results: We studied 887 and 1925 dialysis patients from the United States Renal Data System, who underwent mitral valve replacement and aortic valve replacement (AVR) after being waitlisted for a kidney transplant (2000–2015), respectively. Time to death, time to reoperation, and time to bleeding requiring hospitalizations were compared separately for AVR and mitral valve replacement. Kaplan–Meier survival curves, Cox proportional hazards model for time to death, accelerated time to event model for time to reoperation, and counting process model for time to recurrent bleeding were used. There were no differences in mortality (hazard ratio [HR], 0.92; 95% CI, 0.77–1.09) or risk of reoperation or risk of significant bleeding events between bioprosthetic and mechanical mitral valve replacement. However, mechanical AVR was associated with a modestly significant less hazard of death (HR, 0.83; 95% CI, 0.74–0.94) compared with bioprosthetic AVR. There were no differences in time to reoperation, or time to significant bleeding events between bioprosthetic and mechanical AVR. Conclusions: For kidney transplant waitlisted patients who are on dialysis and who are undergoing surgical valve replacement, bioprosthetic and mechanical valves have comparable survival, reoperation rates, and bleeding episodes requiring hospitalizations at both mitral and aortic locations. These findings emphasize that an individualized informed decision is recommended when choosing the type of valve for this special group of patients having dialysis.
- 2 March 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (5) , e018971
Open AccessOutcomes of Surgical Mitral and Aortic Valve Replacements Among Kidney Transplant Candidates: Implications for Valve Selection
Background: Limited literature exists that evaluated outcomes of kidney transplant–eligible patients who are having dialysis and who are undergoing valve replacement. Our main objective in this study was to compare mortality, reoperation, and bleeding episodes between bioprosthetic and mechanical valve procedures among kidney transplant–eligible patients who are having dialysis. Methods and Results: We studied 887 and 1925 dialysis patients from the United States Renal Data System, who underwent mitral valve replacement and aortic valve replacement (AVR) after being waitlisted for a kidney transplant (2000–2015), respectively. Time to death, time to reoperation, and time to bleeding requiring hospitalizations were compared separately for AVR and mitral valve replacement. Kaplan–Meier survival curves, Cox proportional hazards model for time to death, accelerated time to event model for time to reoperation, and counting process model for time to recurrent bleeding were used. There were no differences in mortality (hazard ratio [HR], 0.92; 95% CI, 0.77–1.09) or risk of reoperation or risk of significant bleeding events between bioprosthetic and mechanical mitral valve replacement. However, mechanical AVR was associated with a modestly significant less hazard of death (HR, 0.83; 95% CI, 0.74–0.94) compared with bioprosthetic AVR. There were no differences in time to reoperation, or time to significant bleeding events between bioprosthetic and mechanical AVR. Conclusions: For kidney transplant waitlisted patients who are on dialysis and who are undergoing surgical valve replacement, bioprosthetic and mechanical valves have comparable survival, reoperation rates, and bleeding episodes requiring hospitalizations at both mitral and aortic locations. These findings emphasize that an individualized informed decision is recommended when choosing the type of valve for this special group of patients having dialysis.
- 29 June 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (8) , e14000
Prescription patterns of opioids and non‐steroidal anti‐inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records
We examined a novel database linking national donor registry identifiers to records from a US pharmaceutical claims warehouse (2007‐2015) to describe opioid and NSAID prescription patterns among LKDs during the first year postdonation, divided into three periods: 0‐14 days, 15‐182 days, and 183‐365 days. Associations of opioid and NSAID prescription fills with baseline factors were examined by logistic regression (adjusted odds ratio, LCLaORUCL). Among 23,565 donors, opioid prescriptions were highest during days 0‐14 (36.6%), but 12.6% of donors filled opioids during days 183‐365. NSAID prescriptions rose from 0.5% during days 0‐14 to 3.3% during days 183‐365. Women filled opioids more commonly than men, and black donors filled both opioids and NSAIDs more commonly than white donors. After covariate adjustment, significant correlates of opioid prescription fills during days 183‐365 included obesity (aOR,1.241.381.53), less than college education (aOR,1.191.311.43), smoking (aOR,1.331.451.58), and nephrectomy complications (aOR,1.111.291.49). NSAID prescription fills in year 1 were not associated with differences in estimated glomerular filtration rate, incidence of proteinuria or new‐onset hypertension at the first and second year postdonation. Prescription fills for opioids and NSAIDs for LKDs varied with demographic and clinic traits. Future work should examine longer‐term outcome implications to help inform safe analgesic regimen choices after donation.
- 29 June 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (8) , e14000
Prescription patterns of opioids and non‐steroidal anti‐inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records
We examined a novel database linking national donor registry identifiers to records from a US pharmaceutical claims warehouse (2007‐2015) to describe opioid and NSAID prescription patterns among LKDs during the first year postdonation, divided into three periods: 0‐14 days, 15‐182 days, and 183‐365 days. Associations of opioid and NSAID prescription fills with baseline factors were examined by logistic regression (adjusted odds ratio, LCLaORUCL). Among 23,565 donors, opioid prescriptions were highest during days 0‐14 (36.6%), but 12.6% of donors filled opioids during days 183‐365. NSAID prescriptions rose from 0.5% during days 0‐14 to 3.3% during days 183‐365. Women filled opioids more commonly than men, and black donors filled both opioids and NSAIDs more commonly than white donors. After covariate adjustment, significant correlates of opioid prescription fills during days 183‐365 included obesity (aOR,1.241.381.53), less than college education (aOR,1.191.311.43), smoking (aOR,1.331.451.58), and nephrectomy complications (aOR,1.111.291.49). NSAID prescription fills in year 1 were not associated with differences in estimated glomerular filtration rate, incidence of proteinuria or new‐onset hypertension at the first and second year postdonation. Prescription fills for opioids and NSAIDs for LKDs varied with demographic and clinic traits. Future work should examine longer‐term outcome implications to help inform safe analgesic regimen choices after donation.
- 17 August 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13696
Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records
We examined a novel linkage of national US donor registry data with records from a pharmacy claims warehouse (2007‐2016) to examine associations (adjusted hazard ratio, LCLaHRUCL) of post‐donation fills of antidiabetic medications (ADM, insulin or non‐insulin agents) with body mass index (BMI) at donation and other demographic and clinical factors. In 28 515 living kidney donors (LKDs), incidence of ADM use at 9 years rose in a graded manner with higher baseline BMI: underweight, 0.9%; normal weight, 2.1%; overweight, 3.5%; obese, 8.5%. Obesity was associated with higher risk of ADM use compared with normal BMI (aHR, 3.364.596.27). Metformin was the most commonly used ADM and was filled more often by obese than by normal weight donors (9‐year incidence, 6.87% vs 1.85%, aHR, 3.555.007.04). Insulin use was uncommon and did not differ significantly by BMI. Among a subgroup with BMI data at the 1‐year post‐donation anniversary (n = 19 528), compared with stable BMI, BMI increase >0.5 kg/m2 by year 1 was associated with increased risk of subsequent ADM use (aHR, 1.031.482.14, P = .04). While this study did not assess the impact of donation on the development of obesity, these data support that among LKD, obesity is a strong correlate of ADM use.
- 17 August 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13696
Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records
We examined a novel linkage of national US donor registry data with records from a pharmacy claims warehouse (2007‐2016) to examine associations (adjusted hazard ratio, LCLaHRUCL) of post‐donation fills of antidiabetic medications (ADM, insulin or non‐insulin agents) with body mass index (BMI) at donation and other demographic and clinical factors. In 28 515 living kidney donors (LKDs), incidence of ADM use at 9 years rose in a graded manner with higher baseline BMI: underweight, 0.9%; normal weight, 2.1%; overweight, 3.5%; obese, 8.5%. Obesity was associated with higher risk of ADM use compared with normal BMI (aHR, 3.364.596.27). Metformin was the most commonly used ADM and was filled more often by obese than by normal weight donors (9‐year incidence, 6.87% vs 1.85%, aHR, 3.555.007.04). Insulin use was uncommon and did not differ significantly by BMI. Among a subgroup with BMI data at the 1‐year post‐donation anniversary (n = 19 528), compared with stable BMI, BMI increase >0.5 kg/m2 by year 1 was associated with increased risk of subsequent ADM use (aHR, 1.031.482.14, P = .04). While this study did not assess the impact of donation on the development of obesity, these data support that among LKD, obesity is a strong correlate of ADM use.
- 11 August 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (9)
Racial disparity in kidney transplant survival relates to late rejection and is independent of steroid withdrawal
Black kidney transplant recipients have more acute rejection (AR) and inferior graft survival. We sought to determine whether early steroid withdrawal (ESW) had an impact on AR and death‐censored graft loss (DCGL) in blacks. From 2006 to 2012, AR and graft survival were analyzed in 483 kidney recipients (208 black and 275 non‐black). Rates of ESW were similar between blacks (65%) and non‐blacks (67%). AR was defined as early (≤3 months) or late (>3 months). The impact of black race, early AR, and late AR on death‐censored graft failure was analyzed using univariate and multivariate Cox models. Blacks had greater dialysis vintage, more deceased donor transplants, and less HLA matching, yet rates of early AR were comparable between blacks and non‐blacks. However, black race was a risk factor for late AR (HR: 3.48 (95% CI: 1.87‐6.47)) Blacks had a greater rate of DCGL, partially driven by late AR (HR with late AR: 5.6; 95% CI: 3.3‐9.3). ESW had no significant interaction with black race for risk of early AR, late AR, or DCGL. Independent of ESW, black kidney recipients had a higher rate of late AR after kidney transplantation. Late AR was highly predictive of DCGL and contributed to inferior graft survival in blacks.
- 11 August 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (9)
Racial disparity in kidney transplant survival relates to late rejection and is independent of steroid withdrawal
Black kidney transplant recipients have more acute rejection (AR) and inferior graft survival. We sought to determine whether early steroid withdrawal (ESW) had an impact on AR and death‐censored graft loss (DCGL) in blacks. From 2006 to 2012, AR and graft survival were analyzed in 483 kidney recipients (208 black and 275 non‐black). Rates of ESW were similar between blacks (65%) and non‐blacks (67%). AR was defined as early (≤3 months) or late (>3 months). The impact of black race, early AR, and late AR on death‐censored graft failure was analyzed using univariate and multivariate Cox models. Blacks had greater dialysis vintage, more deceased donor transplants, and less HLA matching, yet rates of early AR were comparable between blacks and non‐blacks. However, black race was a risk factor for late AR (HR: 3.48 (95% CI: 1.87‐6.47)) Blacks had a greater rate of DCGL, partially driven by late AR (HR with late AR: 5.6; 95% CI: 3.3‐9.3). ESW had no significant interaction with black race for risk of early AR, late AR, or DCGL. Independent of ESW, black kidney recipients had a higher rate of late AR after kidney transplantation. Late AR was highly predictive of DCGL and contributed to inferior graft survival in blacks.
- Open Access
- 1 July 2015
- Published by Elsevier in American Journal of Transplantation
- Vol. 15 (7) , 2006-2008
Fever of Unknown Origin in a Kidney Transplant Recipient
- 1 July 2015
- Published by Elsevier in American Journal of Transplantation
- Vol. 15 (7) , 2006-2008
Open AccessFever of Unknown Origin in a Kidney Transplant Recipient